Initiation of Phase 1b Study of GT-02287 in Parkinson's patients expected by end of 2024 BETHESDA, Md., Nov. 14, 2024 (GLOBE ...

Cantor Fitzgerald analyst Charles Duncan initiated coverage with a Buy rating on Marinus (MRNS – Research Report) yesterday and set a ...

Net Loss: Net loss attributable to common stockholders for the third quarter of 2024 was $ (3.1) million, or $ (1.92) per share, compared to net income of $0.5 million, or $4.86 per share, for the ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

Interim data from initial dose escalation cohorts of Phase 1 CARDINAL trial evaluating TERN-701 (allosteric BCR-ABL tyrosine ...

AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.

The key difference between emraclidine and Cobenfy is that emraclidine is a selective allosteric M4 agonist which means it ...

Reference: Abbott JA, Wen H, Liu B, et al. Allosteric inhibition of NMDA receptors by low dose ketamine. Mol Psychiatry. 2024 ...

Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, 43183 Gothenburg, Sweden ...

Department of Biomolecular Sciences, University of Urbino Carlo Bo, Piazza Rinascimento 6, Urbino 61029, Italy ...